Literature DB >> 16846983

The expression of p63 and cytokeratin 5 in mixed tumors of the canine mammary gland provides new insights into the histogenesis of these neoplasms.

L N Z Ramalho1, A Ribeiro-Silva, G D Cassali, S Zucoloto.   

Abstract

Cytokeratin 5 and p63 have been described as basal and myoepithelial cell markers in human breast. Mixed tumors of the canine mammary gland have been associated with a myoepithelial origin. Cytokeratin 5 expression has not been evaluated in these tumors. We investigated the relation between cytokeratin 5 and p63 double-immunohistochemical expression in 23 mixed tumors of the canine mammary gland (10 benign mixed tumors and 13 carcinomas arising from benign mixed tumors) and their origin. Cytokeratin 5 and p63 co-expression was observed in myoepithelial cells of benign mixed tumors, as well as in squamous differentiation of carcinoma arising from benign mixed tumors. Though a few interstitial spindle cells of the mesenchymal components expressed both p63 and cytokeratin 5, the basal epithelial cells were labeled only by cytokeratin 5. The co-expression of p63 and cytokeratin 5 in myoepithelial cells and squamous differentiation suggest that, like in human breast, cytokeratin 5 can also be considered a myoepithelial- and squamous-cell differentiating marker in canine tumors. The presence of some interstitial spindle cells stained for p63 and cytokeratin 5 might be associated with a myoepithelial origin of the mesenchymal component of mixed tumors of the canine mammary gland. Moreover, contrary to p63, basal epithelial cells were labeled by cytokeratin 5, indicating that cytokeratin 5 may not represent an exclusive myoepithelial cell marker but also a basal epithelial cell marker in canine mixed tumors. According to these data, basal epithelial cells may be related to the origin of the epithelial component of mixed tumors of the canine mammary gland.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16846983     DOI: 10.1354/vp.43-4-424

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  7 in total

Review 1.  A Comparative Review of Mixed Mammary Tumors in Mammals.

Authors:  Eman S A Saad; Jacqueline S Y Lam; Awf A Al-Khan; Mourad Tayebi; Michael J Day; Samantha J Richardson; Janine A Danks
Journal:  J Mammary Gland Biol Neoplasia       Date:  2018-11-28       Impact factor: 2.673

2.  Vitamin D receptor (VDR) expression in different molecular subtypes of canine mammary carcinoma.

Authors:  R Sánchez-Céspedes; M D Fernández-Martínez; A I Raya; C Pineda; I López; Y Millán
Journal:  BMC Vet Res       Date:  2021-05-25       Impact factor: 2.741

3.  Molecular portrait-based correlation between primary canine mammary tumor and its lymph node metastasis: possible prognostic-predictive models and/or stronghold for specific treatments?

Authors:  Germana Beha; Barbara Brunetti; Pietro Asproni; Luisa Vera Muscatello; Francesca Millanta; Alessandro Poli; Giuseppe Sarli; Cinzia Benazzi
Journal:  BMC Vet Res       Date:  2012-11-12       Impact factor: 2.741

4.  Analysis of Contractility and Invasion Potential of Two Canine Mammary Tumor Cell Lines.

Authors:  Kaisa Rajakylä; Ramaswamy Krishnan; Sari Tojkander
Journal:  Front Vet Sci       Date:  2017-09-12

5.  Morphology of the myoepithelial cell: immunohistochemical characterization from resting to motile phase.

Authors:  Germana Beha; Giuseppe Sarli; Barbara Brunetti; Francesco Sassi; Domenico Ferrara; Cinzia Benazzi
Journal:  ScientificWorldJournal       Date:  2012-08-05

6.  P-cadherin expression in feline mammary tissues.

Authors:  Ana Catarina Figueira; Ana Sofia Teodósio; Júlio Carvalheira; Manuela Lacerda; Augusto de Matos; Fátima Gärtner
Journal:  Vet Med Int       Date:  2012-10-03

7.  Canine mammary mixed tumours: a review.

Authors:  Geovanni Dantas Cassali; Angélica Cavalheiro Bertagnolli; Enio Ferreira; Karine Araújo Damasceno; Conrado de Oliveira Gamba; Cecília Bonolo de Campos
Journal:  Vet Med Int       Date:  2012-10-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.